메뉴 건너뛰기




Volumn 83, Issue 5, 2012, Pages 241-247

Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: A pooled analysis of three trials

Author keywords

Anti epidermal growth factor receptor; Cetuximab; Codon 12; KRAS mutation; Metastatic colorectal cancer

Indexed keywords

CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

EID: 84865579878     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000339534     Document Type: Article
Times cited : (26)

References (34)
  • 1
    • 64049090889 scopus 로고    scopus 로고
    • Clinical relevance of EGFRand KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR
    • Heinemann V, Stintzing S, Kirchner T, Boeck S, Jung A: Clinical relevance of EGFRand KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat Rev 2009; 35: 262-271.
    • (2009) Cancer Treat Rev , vol.35 , pp. 262-271
    • Heinemann, V.1    Stintzing, S.2    Kirchner, T.3    Boeck, S.4    Jung, A.5
  • 5
    • 75549090214 scopus 로고    scopus 로고
    • Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer
    • Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A: Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 2009; 205: 858-862.
    • (2009) Pathol Res Pract , vol.205 , pp. 858-862
    • Neumann, J.1    Zeindl-Eberhart, E.2    Kirchner, T.3    Jung, A.4
  • 6
    • 0027254425 scopus 로고
    • Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras. 2 mutation type
    • Finkelstein SD, Sayegh R, Christensen S, Swalsky PA: Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. Cancer 1993; 71: 3827-3838.
    • (1993) Cancer , vol.71 , pp. 3827-3838
    • Finkelstein, S.D.1    Sayegh, R.2    Christensen, S.3    Swalsky, P.A.4
  • 8
  • 9
    • 65349189958 scopus 로고    scopus 로고
    • American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy
    • Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL: American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27: 2091-2096.
    • (2009) J Clin Oncol , vol.27 , pp. 2091-2096
    • Allegra, C.J.1    Jessup, J.M.2    Somerfield, M.R.3    Hamilton, S.R.4    Hammond, E.H.5    Hayes, D.F.6    McAllister, P.K.7    Morton, R.F.8    Schilsky, R.L.9
  • 11
  • 16
    • 79952153189 scopus 로고    scopus 로고
    • Randomized phase III study of 5-fluorouracil/ folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: The NORDIC VII Study (NCT00145314) (abstract LBA20)
    • Tveit K, Guren T, Glimelius B, et al: Randomized phase III study of 5-fluorouracil/ folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: the NORDIC VII Study (NCT00145314) (abstract LBA20). Ann Oncol 2010; 21(suppl 8):9.
    • (2010) Ann Oncol , vol.21 , Issue.SUPPL. 8 , pp. 9
    • Tveit, K.1    Guren, T.2    Glimelius, B.3
  • 22
    • 84866945880 scopus 로고    scopus 로고
    • Diagnostic of KRAS gene mutations in colorectal cancer: Evaluation of direct sequencing, pyrosequencing and allele specific amplification (abstract 1322)
    • Berlin
    • Lamy PJ, Montels F, Servanton AC, Ychou M, Crapez E: Diagnostic of KRAS gene mutations in colorectal cancer: evaluation of direct sequencing, pyrosequencing and allele specific amplification (abstract 1322). ECCO 15 and 34th ESMO Multidisc Congr, Berlin, 2009.
    • (2009) ECCO 15 and 34th ESMO Multidisc Congr
    • Lamy, P.J.1    Montels, F.2    Servanton, A.C.3    Ychou, M.4    Crapez, E.5
  • 28
    • 0032127912 scopus 로고    scopus 로고
    • GTPase-activating proteins: Helping hands to complement an active site
    • Scheffzek K, Ahmadian MR, Wittinghofer A: GTPase-activating proteins: helping hands to complement an active site. Trends Biochem Sci 1998; 23: 257-262.
    • (1998) Trends Biochem Sci , vol.23 , pp. 257-262
    • Scheffzek, K.1    Ahmadian, M.R.2    Wittinghofer, A.3
  • 34
    • 84861802563 scopus 로고    scopus 로고
    • Evaluation of individual codon 12 and 13 mutant KRAS alleles as prognostic and predictive biomarkers of response to panitumumabin patients with metastatic colorectal cancer (mCRC)
    • Peeters M, Douillard YI, van Cutsem E, Siena S, Zhang K, Williams R, Wiezorek J: Evaluation of individual codon 12 and 13 mutant KRAS alleles as prognostic and predictive biomarkers of response to panitumumabin patients with metastatic colorectal cancer (mCRC). EJC 2011; 47(suppl 2):33LBA.
    • (2011) EJC , vol.47 , Issue.SUPPL. 2
    • Peeters, M.1    Douillard, Y.I.2    Van Cutsem, E.3    Siena, S.4    Zhang, K.5    Williams, R.6    Wiezorek, J.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.